Yves Chalandon was born and educated in Geneva, where he obtained board certification in both Internal Medicine and Hematology. He completed a fellowship in hematopoietic stem cell transplantation in Vancouver, conducting research on leukemogenesis under the supervision of Connie Eaves at the Terry Fox Laboratory.
Upon returning to Geneva, he became deeply involved in allogeneic hematopoietic stem cell transplantation (alloHSCT) and the treatment of hematologic malignancies. His research focuses on immune reconstitution following alloHSCT, chronic malignancies through the EBMT's Chronic Malignancies Working Party (CMWP), alloHSCT with the SFGM-TC, and leukemias within the SAKK leukemia group and the GRAALL consortium for acute lymphoblastic leukemia (ALL).
He is an active member of numerous professional societies, including ASH, EHA, EBMT, SSH, SSIM, SAKK, SBST, SFGM-TC, and GRAALL. From 2007 to 2013, he served as president of the SAKK leukemia group and was a member of the SAKK board during the same period.
Since July 2012, he has been Head of the Hemato-Oncology and Bone Marrow Transplantation Unit and Associate Professor in the Hematology Division at the Geneva University Hospitals (HUG). In January 2017, he was appointed Head of the Hematology Division at HUG and since 2021 full professor. He currently chairs the CML Subcommittee of the EBMT’s CMWP and, since 2024, serves as President of the Swiss Society of Hematology.